Matrix metalloproteinase-13 and interleukin-6: A novel diagnostic and therapeutic target for early detection and management of osteoarthritis

Objectives Osteoarthritis (OA) is a common degenerative joint disorder characterized by the breakdown of articular cartilage and bone hypertrophy. Matrix metalloproteinase-13 (MMP-13) and interleukin-6 (IL-6) are two biomolecules that have been linked to the pathogenesis of OA. The early diagnosis and management of OA are critical to prevent disease progression and maintain quality of life. MMP-13 is a key enzyme that contributes to the degradation of cartilage extracellular matrix components, while IL-6 is a proinflammatory cytokine that promotes inflammation and cartilage destruction. Material and Methods The current study attempted to investigate the association of MMP-13 and IL-6 with the severity of clinical condition in OA patients. A total of 225 study subject were enrolled for eligibility from out patients department of orthopedics, Hakeem Abdul Hameed Centenary Hospital (HACH), New Delhi. Ultimately, 112 study subjects were found eligible for study and randomized in healthy control (n=56) and OA (n=56) groups. Results We have found that MMP-13 and serum / urinary IL-6 levels were significantly elevated in OA patients as compared to control group (p<0.05). Interestingly, MMP-13 and IL -6 levels were significantly associate with severity of disease by correlating with kellgren lawrence (KL) grading and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Conclusion The study concludes that MMP -13 and IL -6 may be used as a diagnostic and therapeutic target for the management of OA.